Kelsey Chris R, Clough Robert W, Marks Lawrence B
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Cancer J. 2006 Jul-Aug;12(4):283-8. doi: 10.1097/00130404-200607000-00006.
After surgical resection of non-small cell lung cancer, local/regional recurrence is observed in 20% to 50% of patients, often without evidence of distant metastases. This retrospective study evaluates the utility of salvage radiation therapy in this setting.
Between 1991 and 2003, 29 consecutive patients were treated with definitive radiotherapy (N=14) or chemoradiotherapy (N=15) for recurrent non-small cell lung cancer after surgical resection at Duke University Medical Center. The median time from date of surgery to date of recurrence was 18 months (range, 2-151). At the time of recurrence, most patients had mediastinal adenopathy (N=19), but seven patients had disease confined to the surgical stump and three had hilar adenopathy with (N=2) or without (N=1) a stump recurrence. The median radiation therapy dose was 66 Gy (range, 46-74). Local control and overall survival were estimated using the Kaplan-Meier method. A univariate regression analysis was performed to evaluate the effect of several patient- and treatment-related factors on local control and overall survival.
Median survival after radiation therapy was 17 months. Of the 29 patients, five are alive without evidence of disease 22, 28, 34, 54, and 158 months since completing radiation therapy. Actuarial local control and overall survival at 2 years were 62% and 38%, respectively. There was a trend toward improved survival with younger age and a longer disease-free interval between surgery and local recurrence, but these findings were not statistically significant.
Radiation therapy, with or without chemotherapy, produced a 2-year survival of 38% in our series of patients with local/regional recurrence of non-small cell lung cancer after resection. Aggressive therapy in this population of patients is warranted.
在非小细胞肺癌手术切除后,20%至50%的患者会出现局部/区域复发,且往往无远处转移证据。本回顾性研究评估了挽救性放射治疗在此情况下的效用。
1991年至2003年期间,杜克大学医学中心有29例连续患者在手术切除后接受了针对复发性非小细胞肺癌的根治性放疗(N = 14)或放化疗(N = 15)。从手术日期到复发日期的中位时间为18个月(范围为2至151个月)。复发时,大多数患者有纵隔淋巴结肿大(N = 19),但7例患者疾病局限于手术残端,3例有肺门淋巴结肿大,其中2例伴有残端复发,1例无残端复发。中位放射治疗剂量为66 Gy(范围为46至74 Gy)。使用Kaplan-Meier方法估计局部控制率和总生存率。进行单因素回归分析以评估几个患者和治疗相关因素对局部控制率和总生存率的影响。
放射治疗后的中位生存期为17个月。29例患者中,有5例在完成放射治疗后22、28、34、54和158个月时存活且无疾病证据。2年时的精算局部控制率和总生存率分别为62%和38%。年龄较小以及手术与局部复发之间的无病间隔较长有生存改善的趋势,但这些结果无统计学意义。
在我们这组非小细胞肺癌切除术后局部/区域复发的患者中,无论是否联合化疗,放射治疗的2年生存率为38%。对这组患者进行积极治疗是有必要的。